Specialist pharmacy BioMatrix SpRx revealed on Wednesday the completion of the acquisition of Elwyn Pharmacy Group for undisclosed amount.
Located in Garnet Valley, Pennsylvania, southwest of Philadelphia, Elwyn Pharmacy Group provides a complete range of specialty pharmacy and infusion services. It treats a wide array of complex disease states including Multiple Sclerosis, Hepatitis C and other GI related diseases, Oncology/Cancer, bleeding disorders, Rheumatoid Arthritis, Psoriasis and HIV. The Elwyn Pharmacy Group includes Elwyn Pharmacy, Glen Rock Medical Pharmacy, Elwyn Specialty Care, and Med Center Specialty Pharmacy.
With this acquisition, BioMatrix has expanded their services into complementary therapeutic categories requiring the same high-touch services they are accustomed to providing. The company has doubled its company size as well as added therapeutic categories to portfolio of services.
Upon closing, BioMatrix's national footprint increases to 11 pharmacy locations, nationwide, in key metropolitan locations. Elwyn joins the rapidly growing family of companies that comprise BioMatrix including Matrix Health Group, Factor Support Network, Medex BioCare, and BiologicTx.
Roivant to announce Q3 2026 financial results
HUTCHMED reports positive Phase III results for sovleplenib in wAIHA
Physiomics secures follow-on UK contract for Phase 2 study support
Amgen's UPLIZNA receives US FDA approval
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
AstraZeneca to invest USD2bn in major Maryland manufacturing expansion
European Commission approves Celltrion's Remsima IV liquid formulation
TIRmed Pharma partners with Bachem to advance production of atopic dermatitis therapy
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Vascarta and CUNY report positive preclinical results in glioblastoma treatment